These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24962700)

  • 1. Pleiotropic roles of mTOR complexes in haemato-lymphopoiesis and leukemogenesis.
    Hoshii T; Matsuda S; Hirao A
    J Biochem; 2014 Aug; 156(2):73-83. PubMed ID: 24962700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells.
    Hoshii T; Kasada A; Hatakeyama T; Ohtani M; Tadokoro Y; Naka K; Ikenoue T; Ikawa T; Kawamoto H; Fehling HJ; Araki K; Yamamura K; Matsuda S; Hirao A
    Proc Natl Acad Sci U S A; 2014 Mar; 111(10):3805-10. PubMed ID: 24567410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Roles of mTOR signalings in hematopoiesis and leukemogenesis].
    Hirao A
    Rinsho Ketsueki; 2015 Jun; 56(6):601-5. PubMed ID: 26256868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes.
    Tao Z; Barker J; Shi SD; Gehring M; Sun S
    Biochemistry; 2010 Oct; 49(39):8488-98. PubMed ID: 20804212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.
    Soliman GA; Acosta-Jaquez HA; Dunlop EA; Ekim B; Maj NE; Tee AR; Fingar DC
    J Biol Chem; 2010 Mar; 285(11):7866-79. PubMed ID: 20022946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin and tuberous sclerosis complex.
    Wataya-Kaneda M
    J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin and the kidney. I. The signaling pathway.
    Lieberthal W; Levine JS
    Am J Physiol Renal Physiol; 2012 Jul; 303(1):F1-10. PubMed ID: 22419691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells.
    Jhanwar-Uniyal M; Jeevan D; Neil J; Shannon C; Albert L; Murali R
    Adv Biol Regul; 2013 May; 53(2):202-10. PubMed ID: 23231881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis.
    Huo Y; Iadevaia V; Proud CG
    Biochem Soc Trans; 2011 Apr; 39(2):446-50. PubMed ID: 21428917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia.
    Hirao A; Hoshii T
    Cancer Sci; 2013 Aug; 104(8):977-82. PubMed ID: 23648144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of mTOR in energy and metabolic homeostasis.
    Haissaguerre M; Saucisse N; Cota D
    Mol Cell Endocrinol; 2014 Nov; 397(1-2):67-77. PubMed ID: 25109278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
    Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
    J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [mTORC1 and sirolimus: a link with fertility].
    Tartarin P; Froment P
    Med Sci (Paris); 2013 Feb; 29(2):200-5. PubMed ID: 23452608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stoichiometry and assembly of mTOR complexes revealed by single-molecule pulldown.
    Jain A; Arauz E; Aggarwal V; Ikon N; Chen J; Ha T
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):17833-8. PubMed ID: 25453101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PRAS40 in Akt and mTOR signaling in health and disease.
    Wiza C; Nascimento EB; Ouwens DM
    Am J Physiol Endocrinol Metab; 2012 Jun; 302(12):E1453-60. PubMed ID: 22354785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focus Issue: demystifying mTOR signaling.
    Gough NR
    Sci Signal; 2009 Apr; 2(67):eg5. PubMed ID: 19383973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of mechanistic target of rapamycin in maintenance of glomerular epithelial cells.
    Yao Y; Inoki K
    Curr Opin Nephrol Hypertens; 2016 Jan; 25(1):28-34. PubMed ID: 26625863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
    Dormond-Meuwly A; Roulin D; Dufour M; Benoit M; Demartines N; Dormond O
    Biochem Biophys Res Commun; 2011 Apr; 407(4):714-9. PubMed ID: 21439267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTORC signaling in hematopoiesis.
    Wang X; Chu Y; Wang W; Yuan W
    Int J Hematol; 2016 May; 103(5):510-8. PubMed ID: 26791377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.
    Limon JJ; So L; Jellbauer S; Chiu H; Corado J; Sykes SM; Raffatellu M; Fruman DA
    Proc Natl Acad Sci U S A; 2014 Nov; 111(47):E5076-85. PubMed ID: 25385646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.